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1112-158 Eva luat ion  of  the  Csrd loprotect lve  Effect o f  
Dexrezoxane In Chi ldren Treated With Anthracyc l ine  
Marcelo G. Paiva. Sergio Pstrilli, Addana Cordovil. Cdstiano Mechado, Adelaide Arruda, 
Aden Gil, Valdir Ambroaio, Orlando Campos, Angelo DePaola, Antonio Carvaiho, 
Universidade Federal de San Paulo, S,~o Paulo, Brazil, Hospital Nove de Julho. S~o 
Paulo, Brazil 
Background: Intensive treatment of anthracycline cardiomyopathy may not have had 
impact on mortality as would have expected and so far cardiovascular death is the sec- 
ond leading cause of death in long term survivors of childhood cancer. So, demonstrating 
prevention of early cardiac toxicity induced by doxorrubicin may identify a population with 
less risk for late cardiomyopathy. 
Methods: 37 patients, part of Brazilian multicenter trial for treatment of ostecgenic sar- 
coma were studied. 19 patients (11 male, 19,7 ± 4 years) received doxorrubicin (346.47 ± 
16 rag/m2) (DOXO), and 18 patients (14 male, 16,8 + 5 years) received doxorrubicin 
(396,53 ± 15 mg/m2) plus dexrazoxane (DOXO+DEXRA).A low dose dobutamine stress 
echocardiography (DSE) was performed at least I year after the last chemotherapy (OT). 
Left ventdcular systolic and diastolic functional parameters were evaluated at rest and 
after dobutamine infusion. The results were compared against a group of 21 patients (13 
male, 15 ± 4 years) with osteogenic sarcoma but before QT (CONTROL). 
Results: No major side affects were recorded. Rest echocardiogram demonstrated no 
significant difference between the 3 groups. During DSE. diastolic function had the same 
response, but a less significant improvement was observed on systolic parameters with 
DOXO compared to DOXO+DEXRA and CONTROL. 
DOXO DOXO+DEXRA CONTROL 
REST Fractional Shortening 34% ± 5% 36% ± 5% 36% ± 3% 
DSE Fractional Shortening 42% ± 5%* 47% + 7% 47% ± 7% 
* p<0,05 
Conclusions: Low dose DSE was able to identify a better myocardial performance on 
patients treated with dexrazoxane than those who received antracycline alone. 
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1113-146 Carvedilol in Elder ly  Heart  Fai lure Pat ients  
Chdstonher S. Allada. Anne M. Kecgh, Eugene Kotlyar, Christopher S. Hayward, Peter 
S. Macdonald, St Vincent's Hospital, Sydney, Australia. 
Background: Cervedilol has been shown to improve symptoms and survival in patients with 
all grades of heart failure. However, exbedence is limited with the use of carvedilol in the aid- 
erly. We wished to determine whether there are differences in tolerance of, or responses to 
carvedilol between people greater than or equal to, and less than 65 years of age. 
Methods: In a cohort of 109 elderly patients aged greater than or equal to 65 commenced on 
open label cervedilol between February 1996 and May 2001, 84 (77.1%) have remained on 
cervedilol for more than 12 months. During the same period there have been 385 patients 
aged less than 65 who have commenced on open label carvedilol, and of these people 308 
(80.0%) have remained on carvedilol greater than 12 months. 
Results: Death or transplantalJon resulted in cessation of cervedilol in 11 (10.0%) and 41 
(10.6%) patients in the older and younger aged groups respectively. Cessation due to other 
adverse side effects occurred in 14 (12.8%) and 36 (9.4%) peitents in the older and younger 
aged groups respectively. The 2 groups were not statistically different on chi-squared analy- 
sis. 
_> 65 (n=84) Baseline 3 months 6 months 12 months 
NYHA 3.2 ± 0.7 2.6 + 0.6 * 2.4 ± 0.7 * 2.4 ± 0.7 * 
6MW'F (m) 384 ± 117 440 ± 64 * 419 ± 57 * 434 ± 82 * 
LVEDD (mm) 71±11 69±11 57±10 66±14 
LVESD (ram) 59 ± 12 58 ± 13 55 ± 12 55 ± 16 
FS(%) 0.17±0.07 0.17±0.08 0.19±0.07 0.20±0.09* 
EF(%) 0.29+0.10 0.31 ±0.12 0.34+_0.12" 0.33±0.12" 
< 65 (n=308) Beul lne 3 months 6 months 12 months 
NYHA 2.8 ± 0.8 2.2 + 0.7 * 2.1 ± 0.7 * 2.1 + 0.7 * 
6MWT (m) 442 ± 66 498 ± 90 * 489 ± 105 * 483 ± 194 * 
LVEDD (mm) 74±11 72±11 71±11 * 72+12 
LVEBD (ram) 63±12 59±13"  59±13"  59±14"  
FS(%) 0.15+0.07 0.18±0.07" 0.18±0.07" 0.16±0.07" 
EF(%) 0.25±0.19 0.31 +0.10" 0.31 ±0.10" 0.31 ±0.11 * 
* p<0.05 
Conclusions: Elderly patients with heart failure tend to have more severe limitation at 
baseline. However, elderly people have a similar cessation rate due to adverse reactions 
or the combined end-point of death or transplantation when compared with the younger 
group. Where tolerated, carvedilol produces similar beneficial outcomes in both elderly 
and younger patients. 
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1113-147 Effect  of  Vsrdensf l l ,  s Select ive Phoephod les terase  5 
Inhibitor, on the Cardiovascular Response  to  Exerc ise  
In Men With Coronary Artery  Disease 
Udho ThadanL Arthur Mazzu, the Vardenafil Study Group, Oklahoma University Health 
Science Center, Oklahoma Ci~ Oklahoma, Bayer Corporation, West Haven, 
Connecticut. 
Background: Erectile dysfunction (ED) is common among men with coronary artery dis- 
ease (CAD). It is important o understand the cardiovascular effects of PDE5 inhibitors in 
man with CAD. This study evaluated the effect of vardenafU on treadmill exercise time in 
patients with exertional cardiac ischemia. Methods: In this double-blind, crossover, sin- 
gle-dose, multicenter study, 41 men (48-77 yr) with stable CAD who had reproducible 
exercise tests were randomized to vardenafil 10 mg or placebo, followed by exercise 
treadmill test (E-I-r, 5-10 METS) one hour post-dose, the time of maximal drug exposure. 
Nitrates were prohibited _< 24 hr pre- and post-study. ReBulte: Raiati'~e to placebo, vard- 
enafil did not alter total ETT time or time to awareness of angina pectoris, but did signifi- 
cantly prolon~ the time to ST-segment depression. 
Parameter Vardenafil Placebo Ratio LS Means 
10 mo (vardenafiVolacebo~ 
Treadmill Exercise Time*, sec 433 ±109 427 +105 1.015 (NS) 
n =39 n = 39 
"rime to Angina Pectods*, first 291 ±123 292 ±110 0.976 (NS) 
awareness, sec n = 34 n = 34 
Time to ST-Segment depression _>1 381 ±108 334 ±108 1.155 (p= 0.0004) 
mm/~ from Baseline*, sec n = 31 n = 31 
*mean +SD 
Vardenafil was well tolerated. The most common events during vardenafil administration 
(facial flushing and headache) were mild or moderate and short-lived. Changes in BP, 
HR, or ECG were comparable between vardenafil and placebo groups. Conclusion: 
These study results show that vardenafl110 mg did not impair stable CAD patients' ability 
to exercise at a level exceeding that required for sexual intercourse. 
1113-148 Mltrel Valve Repair in Pat ients  Over  75 Years 
Eric Braunberoer, Patrick Meimoun, Alain Deloche, Rochde Sayah, Jean-Pierre Marino, 
Sylvain Chauvaud, Jean-Paul Cou~til, Alain Berrebi, Jean-No~il Fabiani, Alain 
Carpentier, Hopita/ Europeen Georges Pompidou, Paris, France. 
Background : Valve repair is regarded as the gold standard in the surgery of mitrai valve 
insufficiency (MI). However, the results and indications in patients (pts) over 75 years of 
age are unknown. 
Methods : We reviewed 101 consecutive patients older than 75 who, between February 
1995 and June 2000, underwent elective mitral valve repair for non ischamic mitral valve 
insufficiency (MI). 
Results : The cause of MI was degenerative in 56 pts, extensive annulus calcification in 6, 
rheumatic in 2, bacterial endocarditis in 1 and not specified in 36 pts. An associated func- 
tional thouspid annuloplasty was present in 6 pts. Mean age was 78+/-2.9 years (75-87). 
NYHA functional was II in 55%, til in 44% and IV in I% of the pts. Mean cardiothoracic ratio 
was 53+/-5 (40-70), mean ejection fraction 68+/-11 (40-90) and 23 pts (23%) were in atrial 
fibrillation. Valve analysis showed that 8 pts had a Carpentier functional Type I (normal leaf- 
let motion) MI, 90 pts a Type II (leaflet prolapse) (posterior leaflet 76, anterior leaflet 9, both 
leaflets 5) and 3 a Type III (restricted motion) MI. A remodelling annoloplasty was per- 
formed in all cases but 2. Associated techniques comprised valve resection (83), sliding 
leaflet plasty (5), chordae shortening (5), chordae transposition (6), chordae fenestration 
(3), annulus decalcification (19) and posterior leaflet enlargement (5). 
During the first postoperative month, there were 8 deaths (7,9%).Death rate was much 
higher (5/30;16,7%) in the group of pts over 80 than in the group between 75 and 80 (3/ 
71 ;4,2%) and was not correlated with the complexity of the repair.Two pts (1,9 %) were lost 
to follow-up. Ten died between the third to the 61th month.At the end of the study, 81 pts 
were still alive with a median age of 80,8 +/- 2,9 years (75-88). Follow up extended from 1 
to 74 months (median 36). NYHA class I-III was 21, 53, and 7 respectively. 
Conclusions : 1) Mitral valve repair using Carpentier's techniques provides excellent long 
tem results in patients over 75 with a low pedoperative mortality. 2) Mitral valve repair 
should be discussed in asymptomatic patients below 80 years of age presenting with a 
severe MI. 3) Age is not a contreindication to valve repair in symptomatic patients beyond 
80 years. 
1113-149 Est rogen Rep lacement  Therapy and Card iovascu lar  
Events: The Card iovascu lar  Health Study 
Vera Bittner. Priscilla Vaientgas, Teri A. Manolio, Bruce M. Psaty, John Robbins, Grathe 
S. Tell, Russell P. Tracy, University of Alabama at Birmingham, Birmingham, Alabama. 
Background: Obsarvational studies among middle-aged postmenopausal women sug- 
gest that estrogen-replacement herapy (ERT) reduces the risk of cardiovascular (CV) 
events. It is unknown whether the potential benefits of ERT extend to older women. 
Purpose: To assess the impact of past and current ERT use on death and CV events 
among women enrolled in the Cardiovascular Health Study (CHS). 
Methods: CHS is a prospective cohort study of participants >64 years old. Information 
about ERT use, CV risk factors, and CV history was obtained at baseline. CV events and 
mortality during follow-up were ascertained in standardized fashion and adjudicated by a 
committee blinded to ERT use. Relative risks (RR) of CV events with 95% CI were com- 
puted Using Cox proportional hazards modeling adjusting for age, race, diabetes, alcohol 
use, fibrinogen, and income. Mean follow-up was 5.8+/-1.5 years. 
Results: Current ERT users (n=372) had the most favorable risk profile, past users 
(n=860) were intermediate, and never users (n=2015) had the greatest burden of CV risk 
